Descriptions:
MiniMed CEO — leading the formerly Medtronic Diabetes division that recently re-listed as an independent public company — explains how the company’s closed-loop insulin delivery system functions as what she calls the ‘self-driving car’ of diabetes management. The system pairs a continuous glucose sensor with a proprietary algorithm that doses insulin every five minutes, accounting for 42 known variables that affect blood glucose levels including food, stress, hormones, and illness — effectively replacing the 8 to 10 daily injections required under traditional management.
MiniMed holds a unique position as the only company owning all three components of the automated insulin delivery stack: the sensor, the dosing device (both smart pens and insulin pumps), and the software algorithm. With roughly 640,000 patients across 80 countries on its platform, global adoption sits in the low double digits, representing significant runway. The CEO addresses competition from GLP-1 therapies directly, noting they do not eliminate insulin dependency for type 1 and many type 2 diabetics.
The interview also covers the company’s investor narrative, emphasizing that one quarter of all U.S. healthcare spending is diabetes-related and that better upstream glucose management could significantly reduce downstream costs from cardiovascular disease, kidney failure, and amputations. Clinical evidence generation and physician education are described as the core go-to-market levers in both developed and emerging markets.
📺 Source: Bloomberg Technology · Published May 15, 2026
🏷️ Format: Interview
